Glaukos Corporation announced that Chris M. Calcaterra has been named Chief Operating Officer, effective immediately. Mr. Calcaterra joined Glaukos in 2008 and has served as its Chief Commercial Officer since that time. With his promotion to Chief Operating Officer, Mr. Calcaterra will continue to lead the company’s global sales, marketing and reimbursement functions, while adding oversight of manufacturing operations, facilities management and clinical recruiting to his management responsibilities.
Mr. Calcaterra has more than 25 years of experience in the ophthalmic medical technology industry. Prior to joining Glaukos, he was a senior vice president responsible for the cataract business at Advanced Medical Optics (AMO), which was acquired by Abbott Laboratories in 2009. He previously held increasingly responsible leadership positions in a variety of sales and marketing roles at AMO, as well as AMO’s predecessor surgical division business at Allergan, Inc.
“Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly nine years ago and I am confident that he will continue to play an integral role in our success in the newly created Chief Operating Officer position,” Thomas Burns, Glaukos President and Chief Executive Officer, said in a company news release. “His sales and marketing prowess, thoughtful leadership, sound judgement, competitive spirit and stellar reputation across the ophthalmic professional community and industry make him an ideal individual for this expanded leadership responsibility. On behalf of the entire Glaukos organization, I am pleased to offer Chris this promotion and our congratulations and full support.”
Mr. Calcaterra holds a bachelor’s degree from Miami University and a master’s in business administration from Xavier University.